Ensayos clínicos

Inclusion Criteria:

- All Parts: Participants must have disease that is relapsed, refractory, or intolerant
to standard of care. Participants must have histologically or cytologically confirmed
metastatic malignancy.

- Participants must have one of the following tumor types:

- Parts A and B: Participants must have unresectable cutaneous melanoma.

- Part C: Participants must have one of the following tumor types:

- Cutaneous Melanoma

- Non-small Cell Lung Cancer (NSCLC)

- Colorectal Cancer (CRC)

- Pancreatic Cancer

- Mesothelioma

- For participants with cutaneous melanoma

- Must have been previously treated with an anti-programmed death-1 (anti-PD-1) or
anti-programmed death ligand-1 (anti-PD-L1) agent given alone or with other
therapies.

- Participants with a targetable BRAF mutation must have been treated with, been
intolerant of, or declined treatment with BRAF/MEK targeted therapy prior to
study entry.

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

- Measurable disease per RECIST v1.1 at baseline

Exclusion Criteria:

- History of another malignancy within 3 years before the first dose of study drug, or
any evidence of residual disease from a previously diagnosed malignancy.

- Active central nervous system metastases or leptomeningeal disease. Participants with
previously treated brain metastases may participate provided they are:

- clinically stable for at least 4 weeks prior to study entry after brain
metastasis treatment,

- they have no new or enlarging brain metastases,

- and are off of corticosteroids prescribed for symptoms associated with brain
metastases for at least 7 days prior to the first dose of study drug.

- Prior therapies cannot include any drugs targeting CD228 or 4-1BB

- Immunotherapy, biologics, and/or other approved or investigational antitumor treatment
that is not completed 4 weeks prior to first dose of study drug, or within 2 weeks
prior to the first dose of study drug if the underlying disease has progressed on
treatment

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/9/23. Questions regarding updates should be directed to the study team contact